secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2022-03-15T23:59:59+00:00
Accession:  0001680367-22-000007
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs reports Q4 net income $7.8M, cash $268.8M; presents initial clinical data for SL-172154 and SL-279252
--------------------------------------------------------------------------------

- Q4 2021 net income $7.8M ($0.18 diluted) vs net loss $12.0M in Q4 2020; full year net loss $45.0M vs $36.6M.
- Revenue $30.1M in Q4 (up from $1.3M) due to Takeda collaboration revenue recognition; R&D expenses $16.2M.
- Cash $268.8M as of Dec 31, 2021, sufficient into second half 2024.
- Initial clinical data for SL-172154 in ovarian cancer showed favorable safety, target occupancy, and CD40 activation; combination trial planned.
- SL-279252 showed anti-tumor activity including partial response in ocular melanoma; dose escalation continues to 24 mg/kg.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036722000007/0001680367-22-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036722000007/sttk-20220315.htm
  HTML page:      https://secwatch.observer/filing/0001680367-22-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer